NO131754B - - Google Patents
Download PDFInfo
- Publication number
- NO131754B NO131754B NO1838/71A NO183871A NO131754B NO 131754 B NO131754 B NO 131754B NO 1838/71 A NO1838/71 A NO 1838/71A NO 183871 A NO183871 A NO 183871A NO 131754 B NO131754 B NO 131754B
- Authority
- NO
- Norway
- Prior art keywords
- rcn
- molecular weight
- complex
- approx
- interferon
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 claims description 11
- 108010050904 Interferons Proteins 0.000 claims description 11
- 229940079322 interferon Drugs 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 5
- 101001066878 Homo sapiens Polyribonucleotide nucleotidyltransferase 1, mitochondrial Proteins 0.000 claims description 4
- 102000002681 Polyribonucleotide nucleotidyltransferase Human genes 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- ZWIADYZPOWUWEW-XVFCMESISA-N CDP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O1 ZWIADYZPOWUWEW-XVFCMESISA-N 0.000 claims description 3
- JPXZQMKKFWMMGK-KQYNXXCUSA-N IDP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 JPXZQMKKFWMMGK-KQYNXXCUSA-N 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 238000006872 enzymatic polymerization reaction Methods 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 19
- 229920001519 homopolymer Polymers 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 108010083644 Ribonucleases Proteins 0.000 description 7
- 102000006382 Ribonucleases Human genes 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000000527 sonication Methods 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 3
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 241000711941 Murine orthopneumovirus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 231100000916 relative toxicity Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3789670A | 1970-05-15 | 1970-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO131754B true NO131754B (fr) | 1975-04-14 |
Family
ID=21896942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO1838/71A NO131754B (fr) | 1970-05-15 | 1971-05-14 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US3666646A (fr) |
| AR (1) | AR199872A1 (fr) |
| BE (1) | BE767190A (fr) |
| CA (1) | CA985677A (fr) |
| DE (1) | DE2124123A1 (fr) |
| ES (1) | ES391016A1 (fr) |
| FR (1) | FR2100660B1 (fr) |
| GB (1) | GB1355516A (fr) |
| HU (1) | HU164639B (fr) |
| IE (1) | IE35215B1 (fr) |
| IL (1) | IL36772A0 (fr) |
| NL (1) | NL7105076A (fr) |
| NO (1) | NO131754B (fr) |
| SU (1) | SU421202A3 (fr) |
| ZA (1) | ZA712259B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0113162B1 (fr) * | 1982-09-16 | 1989-07-19 | Hem Research, Inc. | Effet antinéoplastiques des acides ds-ribonucléiques sur les cellules des tumeurs |
| US6780429B1 (en) | 1999-02-15 | 2004-08-24 | Nippon Shinyaku Co., Ltd. | Chain-shortened polynucleotide and method for preparation thereof |
| WO2006054129A1 (fr) * | 2004-11-19 | 2006-05-26 | Institut Gustave Roussy | Traitement ameliore du cancer par arn double brin |
| AU2005332599B2 (en) * | 2005-06-08 | 2012-02-16 | Yisheng Biopharma (Singapore) Pte. Ltd. | Polyinosinic acid-polycytidylic acid-based adjuvant |
| US20070166239A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant |
| US20070166800A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant |
| EP2116602A1 (fr) | 2008-05-07 | 2009-11-11 | Institut Gustave Roussy | Combinaison de produits pour traiter le cancer |
| US20130195919A1 (en) | 2010-03-05 | 2013-08-01 | President And Fellows Of Harvard College | Induced dendritic cell compositions and uses thereof |
| EP4329761A1 (fr) | 2021-04-28 | 2024-03-06 | ENYO Pharma | Potentialisation forte d'effets d'agonistes de tlr3 à l'aide d'agonistes de fxr en tant que traitement combiné |
-
1970
- 1970-05-15 US US37896A patent/US3666646A/en not_active Expired - Lifetime
-
1971
- 1971-04-08 ZA ZA712259A patent/ZA712259B/xx unknown
- 1971-04-15 NL NL7105076A patent/NL7105076A/xx not_active Application Discontinuation
- 1971-05-04 IL IL36772A patent/IL36772A0/xx unknown
- 1971-05-05 CA CA112,273A patent/CA985677A/en not_active Expired
- 1971-05-10 GB GB1405071*[A patent/GB1355516A/en not_active Expired
- 1971-05-10 SU SU1657112A patent/SU421202A3/ru active
- 1971-05-10 ES ES391016A patent/ES391016A1/es not_active Expired
- 1971-05-11 IE IE592/71A patent/IE35215B1/xx unknown
- 1971-05-12 FR FR7117104A patent/FR2100660B1/fr not_active Expired
- 1971-05-13 AR AR235517A patent/AR199872A1/es active
- 1971-05-14 DE DE19712124123 patent/DE2124123A1/de not_active Withdrawn
- 1971-05-14 BE BE767190A patent/BE767190A/fr unknown
- 1971-05-14 HU HUME1359A patent/HU164639B/hu unknown
- 1971-05-14 NO NO1838/71A patent/NO131754B/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR199872A1 (es) | 1974-10-08 |
| ES391016A1 (es) | 1974-04-01 |
| GB1355516A (en) | 1974-06-05 |
| IE35215L (en) | 1971-11-15 |
| NL7105076A (fr) | 1971-11-17 |
| FR2100660B1 (fr) | 1975-06-06 |
| ZA712259B (en) | 1972-11-29 |
| US3666646A (en) | 1972-05-30 |
| HU164639B (fr) | 1974-03-28 |
| CA985677A (en) | 1976-03-16 |
| IE35215B1 (en) | 1975-12-10 |
| DE2124123A1 (de) | 1971-12-02 |
| FR2100660A1 (fr) | 1972-03-24 |
| SU421202A3 (ru) | 1974-03-25 |
| IL36772A0 (en) | 1971-07-28 |
| BE767190A (fr) | 1971-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gottschalk | The chemistry and biology of sialic acids and related substances | |
| Ogilvie | Extracellular functions for ApnA | |
| Kim et al. | Potential anti-AIDS drugs. 2', 3'-Dideoxycytidine analogs | |
| Kandutsch et al. | Studies on a substance that promotes tumor homograft survival (the" enhancing substance"): Its distribution and some properties | |
| AU634199B2 (en) | Heparin fragments as inhibitors of smooth muscle cell proliferation | |
| US5041426A (en) | Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides | |
| NO131754B (fr) | ||
| TR199701539T1 (xx) | C-4'Modifiye edilmi� adenosin kinaz inhibit�rleri. | |
| BR8803442A (pt) | Polissacarideo,processo para a preparacao de polissacarideos,medicamento para uso humano ou animal e aditivo alimentar | |
| BG66191B1 (bg) | Полизахариди с антитромболитична активност, които съдържат поне една ковалентна връзка с биотин или производно на биотин | |
| DE3924424A1 (de) | Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung | |
| Watson | The involvement of cyclic nucleotide metabolism in the initiation of lymphocyte proliferation induced by mitogens | |
| EA032748B1 (ru) | Низкомолекулярный биотехнологический хондроитин 6-сульфат для предупреждения остеоартрита | |
| CN1418103A (zh) | 谷氨酸n－衍生物的多糖酯 | |
| DE58907570D1 (de) | Verwendung von bicyclischen Imidazol-Verbindungen zur Behandlung von Hyperaldosteronismus. | |
| Vancraeyneste et al. | Short fungal fractions of β-1, 3 glucans affect platelet activation | |
| Kelley et al. | Furanose-pyranose isomerization of reduced pyrimidine and cyclic urea ribosides | |
| JP2019501263A (ja) | 硫酸化ヘパリン由来オリゴ糖及びその調製法と施用 | |
| HUT70945A (en) | Compositions for the regulation of cytokine activity contg. oligosaccharides and process to prepare them | |
| Robins et al. | Nucleic acid related compounds. 27." Virtual coupling" of the anomeric proton of cyclic 2'-deoxynucleoside 3', 5'-monophosphates. Reassessment of conformation using praseodymium shifts and assignment of H-2', 2 signals by biomimetic deuteration at C-2' | |
| EP0410002A1 (fr) | Medicament anti-hiv | |
| KR20090109105A (ko) | 바이오틴 또는 바이오틴 유도체와의 1개 이상의 공유 결합을 포함하는 헤파린, 이의 제조 방법 및 이의 용도 | |
| Dische et al. | GLYCOPROTEINS OF SUBMAXILLARY SALIVA OF THE CAT: DIFFERENCES IN COMPOSITION PRODUCED BY SYMPATHETIC AND PARASYMPATHETIC NERVE STIMULATION 1 | |
| Hardingham et al. | The glycosaminoglycans of neonatal rat skin | |
| Mommaerts et al. | Dephosphorlation of Adenosine Triphosphate in Muscular Contraction |